Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Axiom Bio

Request full access

Eliminates molecular toxicity using predictive models

San Francisco, United StatesFounded 2024Biotech & Life Sciences

About Axiom Bio

Axiom Bio is a San Francisco-based biotechnology firm operating at the intersection of machine learning, biochemistry, and life sciences. The company was founded in late 2023 by CEO Brandon White and CTO Alex Beatson, both of whom have dedicated their careers to applying machine learning to computational biology and have experience from companies like Freenome, Spring Discovery, and Genesis Therapeutics. Axiom Bio is focused on addressing the significant challenge of drug-induced toxicity, which is a major cause of clinical trial failures and post-market drug withdrawals.

The company's core business revolves around providing highly accurate and affordable predictive models to help pharmaceutical and biotech researchers identify molecular toxicity early in the drug development process. To achieve this, Axiom has developed what it describes as the world's largest proprietary human toxicity dataset. This was built by screening over 115,000 small molecules on primary human liver cells and capturing detailed data through advanced imaging and biochemical readouts. The dataset is paired with pharmacokinetic measurements and curated clinical outcome data to train Axiom's AI models. The platform's goal is to replace expensive, time-consuming, and often poorly predictive animal testing with in-silico models that run solely on a molecule's structure.

Axiom's primary offering is an AI-driven platform that assesses the risk of drug candidates, with an initial focus on hepatotoxicity (liver injury). The models can untangle complex toxicity pathways, including mitochondrial toxicity, ER stress, and ROS formation, providing a deep mechanistic understanding of a compound's effects. For its clients in the pharmaceutical industry, this service offers a substantial value proposition: the ability to make better-informed decisions, de-risk development pipelines, and bring safer drugs to the clinic more efficiently. The cost per compound is reported to be between $100 and $450, a fraction of the $3,000–$15,000 cost for physical experiments, while demonstrating performance that matches or exceeds traditional lab-based assays. In April 2025, the company announced it had raised $15 million in seed funding from investors including Amplify Partners, Dimension Capital, and Zetta Ventures.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2024
Headquarters
San Francisco, United States
Employees
26
Open positions
4
Dealroom signal
73.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Core AI, Biotech and Pharma, AI Applications, DT and LS, science-based
Technology
Artificial Intelligence
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Apr 2025 $15M $60M Amplify Partners · Dimension · Zetta Venture Partners ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Axiom Bio website traffic

Latest recorded traffic for Axiom Bio is 17K monthly website visits, down 10.5% over the last three months.

Latest monthly visits17K 3-month web change-10.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Axiom Bio in the San Francisco ecosystem

Live from Dealroom

The Axiom Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

Other known investors2 additional known investors

  • Inception Studio
  • Stef van Grieken
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States86.4%
🇨🇦 Canada9.1%
🇮🇱 Israel4.5%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Axiom Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Axiom Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.